» Articles » PMID: 38721358

Effect of Food on Selumetinib Pharmacokinetics and Gastrointestinal Tolerability in Adolescents with Neurofibromatosis Type 1-related Plexiform Neurofibromas

Overview
Journal Neurooncol Adv
Date 2024 May 9
PMID 38721358
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Selumetinib is approved for the treatment of pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) in multiple countries, including the USA (≥ 2 years). Until recently, individuals had to take selumetinib twice daily (BID) in a fasted state. This study evaluated the effect of a low-fat meal on selumetinib PK parameters and gastrointestinal (GI) tolerability in adolescent participants with NF1-PN.

Methods: Eligible participants aged ≥ 12 to < 18 years took 25 mg/m selumetinib BID with a low-fat meal (T1) for 28 days, followed by a 7-day washout, and then administration in a fasted state (T2) for another 28 days. Primary objectives were to evaluate the effect of a low-fat meal on AUC and GI tolerability after multiple selumetinib doses in T1 versus T2. Key secondary objectives were additional PK parameters and adverse events (AEs).

Results: At primary data cut-off, all 24 participants completed T1, and 23 participants completed T2. There were no significant differences in AUC between T1 and T2. In T1 and T2, 29.2% and 33.3% participants, respectively, reported ≥ 1 GI AE. No GI AEs Grade ≥ 3, or serious AEs, or GI AEs resulting in treatment interruptions, discontinuation, or dose reductions were reported in T1 and T2.

Conclusions: Dosing selumetinib with a low-fat meal had no clinically relevant impact on selumetinib AUC nor GI tolerability in adolescents with NF1-PN.

Trial Registration Clinicaltrialsgov Id: NCT05101148.

Citing Articles

A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.

Curlee M, Toledo-Tamula M, Baker M, Wikstrom D, Harrison C, Rhodes A Cancers (Basel). 2025; 17(2).

PMID: 39858077 PMC: 11763577. DOI: 10.3390/cancers17020295.

References
1.
Baldo F, Magnolato A, Barbi E, Bruno I . Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change. BMC Pediatr. 2021; 21(1):67. PMC: 7866429. DOI: 10.1186/s12887-021-02530-5. View

2.
Nguyen R, Ibrahim C, Friedrich R, Westphal M, Schuhmann M, Mautner V . Growth behavior of plexiform neurofibromas after surgery. Genet Med. 2013; 15(9):691-7. DOI: 10.1038/gim.2013.30. View

3.
Lane M, Czyzewski D, Chumpitazi B, Shulman R . Reliability and validity of a modified Bristol Stool Form Scale for children. J Pediatr. 2011; 159(3):437-441.e1. PMC: 3741451. DOI: 10.1016/j.jpeds.2011.03.002. View

4.
Gross A, Wolters P, Dombi E, Baldwin A, Whitcomb P, Fisher M . Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020; 382(15):1430-1442. PMC: 7305659. DOI: 10.1056/NEJMoa1912735. View

5.
Schalkwijk S, Zhou L, Cohen-Rabbie S, Jain L, Freshwater T, So K . Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemother Pharmacol. 2021; 88(2):189-202. DOI: 10.1007/s00280-021-04274-6. View